Replies to post #80692 on Biotech Values

[genisi]

The pramlintide/leptin phase IIa trial enrolled overweight and obese patients with a BMI of 27-35 kg/m2. Think this subgroup might be too 'light' to tolerate 2xday injections.

[brainlessone]

that subgroup is the largest target market